Phaseline

Companies › Sirnaomics

Sirnaomics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Other; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
STP705
siRNA targeting TGF-β1 and COX-2 for inflammation and adipose tissue remodeling inhibition
TGFB1, PTGS2Phase 2Submental FullnessJul 2027
FXI-GalNAc-siRNA
Factor XI silencing RNA (GalNAc-conjugated siRNA)
F11Phase 1FXIMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05844293FXI-GalNAc-siRNAPhase 1FXIOtherMay 2027
NCT07677683STP705Phase 2Submental FullnessOtherJul 2027

Targets

TGFB1 (1) PTGS2 (1) F11 (1)

Companies with the same targets

Bristol-Myers Squibb Laboratorios Silanes S.A. de C.V. Regeneron Pharmaceuticals FBD Biologics Kolon TissueGene Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Bicara Therapeutics ZetrOZ Caribou Biosciences Sana Biotechnology

Companies built like this

Tortugas Neuroscience Mylan Pharmaceuticals Shanghai Argo Biopharmaceutical AFT Pharmaceuticals Healx

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.